Stanton Gerson, a Distinguished University Professor, the Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology, and director of the Case Comprehensive Cancer Center, was one of more than 50 leading oncologists in the U.S. that co-authored a report in The Lancet Oncology that sets out how to accelerate cancer research and care.
The report, “The Lancet Oncology Commission on Future Research Priorities in the USA,” sets out a detailed roadmap to deliver on the Blue Ribbon Panel recommendations, including a focus on prevention, a new model for drug discovery and development, a vast expansion of patient access to clinical trials, and an emphasis on targeted interventions to improve cancer care for underserved groups, specifically children, cancer survivors and minority groups. The report emphasizes the importance of addressing health disparities in all recommendations.
The report also examines ways to deliver on the U.S. Cancer Moonshot initiative, and identifies 13 key priority areas in which to focus the $2 billion of funding released to the National Cancer Institute as part of the 21st Century Cures Act.
The commission launched Nov. 1 at an event on Capitol Hill in Washington, D.C. and will be presented Nov. 3 at the United Nations Association of New York Humanitarian Awards, where former Vice President Joe Biden is being honored for his work on improving cancer outcomes as part of the US Cancer Moonshot Initiative.
Learn more about the commission at thelancet.com/commissions/usa-oncology.